News
Arizona Symposium on Patient Self-Advocacy — August 22
The Arizona Carcinoid & Neuroendocrine Foundation, Inc. (AZCNF) invites you to attend VOICES: A Symposium on Patient Self-Advocacy on Tuesday, August 22 at the Banner MD Anderson Cancer Center in Gilbert, Arizona. The theme of VOICES…
READ MORENow Available on Demand — Patient Education on Carcinoid Syndrome from Diagnosis to Treatment
Watch now, program recorded live on March 1, 2017! Whether you are a newly diagnosed neuroendocrine cancer patient with carcinoid syndrome or have been living with carcinoid syndrome for years, this interactive program with a neuroendocrine tumor …
READ MORELearning to Speak Up with Cancer
Do you have concerns about speaking with your doctor? Wonder how to convey what you are feeling physically and emotionally? Josh Mailman’s newly published article in CURE, “What stands in the way of patient-physician communications and how can …
READ MORENET Specialist David C. Metz, MD Receives Prestigious AGA Recognition Award
Congratulations to Dr. David C. Metz, Co-Director of the Neuroendocrine Tumor Center at Penn Medicine, who has received the American Gastroenterological Association (AGA) Distinguished Clinician Award, Clinical Academic Practice. The AGA cited…
READ MORENeuroendocrine Tumors on TV: Rare Disease Day Special, February 28, 2017
NETs on TV! The Carcinoid Cancer Foundation teamed up with The Balancing Act and Advanced Accelerator Applications to raise awareness about carcinoid and neuroendocrine tumors (NETs) during a feature on Lifetime TV on February 28 (Rare Disease Day)…
READ MOREBreaking News on Rare Disease Day — FDA Approves New Drug for Carcinoid Syndrome Diarrhea
On February 28, 2017, the US Food and Drug Administration (FDA) approved XERMELO™ (telotristat ethyl) 250 mg as a first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog…
READ MOREInterested in Carcinoid/Neuroendocrine Tumor Research?
The Carcinoid Cancer Foundation and our partner Self Care Catalysts are currently recruiting patients with carcinoid and other neuroendocrine tumors (NETs) for a research study which involves the use of the Carcinoid NETs Health Storylines mobile…
READ MOREAdvocating for the Neuroendocrine Tumor Community
Congratulations and with appreciation to Stacie Chevrier who has been appointed a Patient Representative with the U.S. Food and Drug Administration (FDA) to represent the Neuroendocrine Tumor community. Stacie writes that she will “be involved…
READ MORENETSPOT Gallium-68 Code for Medicare/Medicaid and Private Payors
Another exciting step forward for the NET community! Advanced Accelerator Applications announced that the Centers for Medicare & Medicaid Services (CMS) has granted NETSPOT® Transitional Pass-Through Status under an “A-code” (A9587)…
READ MORESpeaking Up: What Stands in the Way of Patient-Physician Conversation about Neuroendocrine Tumors and Carcinoid Syndrome
Members of the neuroendocrine tumor (NET) community are invited to attend an informal discussion, hosted by Lexicon Pharmaceuticals, about the barriers and opportunities in discussing NETs and carcinoid syndrome with your healthcare professional…
READ MORE
PROUD PAGE SPONSOR
